S. Redhu

发表

A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†.

D. Planchard, P. Jänne, M. Ahn, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.